We discussed a number of things including: 

1. State of the entrepreneurial community in the region and worldwide 

2. Investment outlook in various sectors in short and medium term 

3. Advice for entrepreneurs as we look to the other side of the pandemic 

Steve has been a technology investor for over twenty years. Steve’s interests are in enterprise software (particularly applications of AI/ML), infrastructure required to collect, store, and process data, internet of things, wireless, and environmental and materials technologies. He is currently on the board of ChoiceWORX, Data Inventions, Kintra Fibers, SunRay Scientific, and Vydia. He was recently a director of Airclic (sold to Descartes Systems), Alverix (sold to BD), Everspin Technologies (NASDAQ: MRAM), Neohapsis (sold to Cisco), Silicon Hive (sold to Intel), Sychip (sold to Murata), and an observer of Flarion Technologies (sold to Qualcomm). 

Steve has also been a leader in the corporate venture community and was Chair of the Corporate Venture Group within the National Venture Capital Association and on the Advisory Board of Global Corporate Venturing. 

Prior to Tech Council Ventures, he created a venture incubator for Lucent’s Bell Laboratories for 5 years and then formed and ran New Venture Partners for 15 years investing in commercialization of technologies spun out of corporate labs. 

Steve received an MBA from The Amos Tuck School at Dartmouth College where he is currently on the board of the Center for the Study of VC & PE. He received degrees in economics and mathematical sciences from Stanford University. 

---- 

Daniella has been building life sciences businesses, developing and commercializing life sciences products for 20 years. Having co-founded Wave Biotech LLC from her dormitory room, she and a partner drove the start-up, growth and commercialization of a highly disruptive technology. As Vice President of the organization, Daniella established a high growth company with significant brand recognition, and led the group to a successful exit and acquisition by GE Healthcare in 2007. At GE Healthcare, 

Daniella held a variety of strategic, M&A and business development roles. One of her most notable achievements is the success in an entrepreneurial group within the broader GE Healthcare, where a focus on integrating the acquired Xcellerex business enabled global commercialization of a several hundred million dollar enterprise solutions business. Her extensive business development, negotiations and deal-making experience with multinational biopharma and governments in developed and emerging markets provides Dynamk with a broad network of colleagues, customers, innovators and key opinion leaders. 

She holds a B.E. in Chemical Engineering from Stevens Institute of Technology and an Executive MBA from New York University Stern School of Business and has attended Harvard Business School Executive Education Courses in Private Equity & Venture Capital.